Targeting BCR signaling with oral kinase inhibitors has changed the treatment landscape in MCL, but this approach seems to be limited by primary or secondary resistance in aggressive B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) [43]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.